Variability in laboratory parameters used for management of Cushing&apos;s syndrome by F. Pecori Giraldi & A.G. Ambrogio
ENDOCRINE METHODS AND TECHNIQUES
Variability in laboratory parameters used for management
of Cushing’s syndrome
Francesca Pecori Giraldi1,2 • Alberto G. Ambrogio2
Received: 8 April 2015 / Accepted: 24 June 2015 / Published online: 10 July 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract The progress in assay methodology, from the
use of radioactive tracers to chemiluminescent signals,
from competitive to chromatographic techniques and from
serum or urine to saliva has considerably impacted on
hormonal measurements. The clinician now may choose
among multiple tests but the inherent variability in cortisol
and ACTH secretion, coupled to lack of harmonization
among assay procedures and normal ranges mandates
careful interpretation of any result. The present review will
examine factors which affect interpretation of cortisol and
ACTH measurements and their impact on tests used for
management of Cushing’s syndrome.
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The management of Cushing’s syndrome rests on the
determination of the two main hormones of the hypotha-
lamic-pituitary-adrenal (HPA) axis, namely cortisol and
ACTH. These may be measured in serum and urine, in the
early morning, at night, or over 24 h as well as at baseline
or after specific challenges. The endocrinologist is called to
interpret the resulting hormone measurements on the basis
of a large body of studies describing cut-offs to be used in
order to exclude or confirm the initial clinical suspicion and
establish the etiology of hypercortisolism. In all these sit-
uations, clinicians rely heavily on assay results, i.e., a
number which represents hormone concentration. This
number, however, has to be interpreted taking into account
the fact that both cortisol and ACTH are secreted with
considerable circadian and ultradian variation and, further,
commutability of assays performed in large-scale non-en-
docrine laboratories may not meet requirements for fine
endocrine diagnosis, e.g., overestimation, non-linear bias.
Indeed, the gap between assay procedures and diagnostic
criteria established at referral centers and the results of field
assays used in routine clinical practice—which are mostly
chosen on economic and logistical basis—is widening. In
this context, it is worth recalling that although Cushing’s
syndrome is a rare disorder and usually managed by ded-
icated endocrinologists, the burden of the initial suspicion
and diagnostic work-up rests squarely on the general
endocrine clinic thus both practitioners will be called into
play.
Several factors are likely to contribute to the variability
in cortisol and ACTH measurements. The present paper
will discuss these issues and their impact on tests used for
the management of Cushing’s syndrome in order to provide
an up-to-date review for the general and specialist
endocrinologist alike.
Urinary free cortisol
Determination of urinary free cortisol (UFC) is historically
the premier measure for the diagnosis of Cushing’s syn-
drome but its reliability has come to be questioned in the
past few years [1]. Further, although severity of Cushing’s
syndrome is often gauged by UFC levels and patients with
extremely high levels are prone to develop the most severe
complications [2, 3], a strict correlation between UFC
concentrations and clinical signs of hypercortisolism may
& Francesca Pecori Giraldi
fpg@auxologico.it
1 Department of Clinical Sciences and Community Health,
University of Milan, Milan, Italy
2 Neuroendocrinology Research Laboratory, Istituto
Auxologico Italiano, Via Zucchi 18, 20095 Milan, MI, Italy
123
Endocrine (2015) 50:580–589
DOI 10.1007/s12020-015-0676-9
not be readily detectable [4]. This impacts the interpreta-
tion of treatment responses and detection of disease
recurrence, as changes in UFC are not always accompanied
by parallel amelioration or worsening of clinical features.
Several factors are responsible for the increasing doubts
as to the reliability of UFC as a marker of endogenous
hypercortisolism. One of the key problems is likely to be
assay-related as methods for measuring UFC have changed
considerably over the past decades but problems related to
cortisol metabolites and conjugates continue to interfere
with accurate measurement of cortisol itself [5]. In
immunoassays, with either radioactive or chemilumines-
cent tracers, antibodies are raised against protein-conju-
gated cortisol and antibody specificity inevitably varies [6].
Many cortisol metabolites, e.g., free or conjugated
tetrahydro-, 20dihydro-, 6ß-hydrocortisol/cortisone, and
cortols, as well as other as yet unidentified steroids, are
secreted in urine and may cross-react with the antibody [7].
Cross-reactivity with 11-deoxycortisol must be excluded in
patients on metyrapone, as levels of this steroid increase
due to 11ß-hydroxylase blockade [8]. Metabolites are
usually excreted in far greater amounts than cortisol itself,
thus even small interferences will translate into gross
overestimation of ‘‘urinary free cortisol.’’ Solvent extrac-
tion with dichloromethane removes most polar cortisol
metabolites, e.g., glucuronides and sulfates, thereby
reducing values by two or three times [9]; indeed, upper
limits of the normal range reported by direct urine assays
are roughly twice as high as those reported in extracted
urine (approx. 150 lg/24 h or 410 nmol/l24 h vs 80 lg/
24 h or 220 nmol/24 h, respectively). Chromatographic
methods, i.e., high-performance liquid chromatography,
liquid, or gas chromatography followed by mass or tandem
mass spectrometry, are currently advocated as the most
accurate means of measuring cortisol in urine [10] but are
as yet not widely available both in terms of equipment and
technical expertise. This obviously represents a drawback
for routine clinical practice. Chromatographic methods
achieve greater specificity, in fact cortisol measurements
are roughly half those reported by immunoassays [11], but
are subject to interferences (‘‘matrix effects’’) which may
affect accuracy and reproducibility [12]. Altogether, qual-
ity assessment programs revealed from 20 to nearly 60 %
interassay variability in routine UFC measurements [13].
It should also be recalled that cortisol is secreted in a
highly pulsatile fashion, with considerable diurnal fluctu-
ations. Day-to-day variability of UFC has been estimated
around 40 % [14] and excursions may be even larger in
patients with Cushing’s syndrome [4, 15] (Fig. 1). This
obviously does not allow clinicians to rely on a single
determination as a comprehensive measure of hypercorti-
solism or even the mean of three [4]. In fact, it has been
estimated that up to ten measurements are required to
achieve reliability of the mean value [16]. This has to be
taken into account when repeat UFC measurements are
performed, for example, to interpret response to medical
treatments [17, 18] or to follow progression of recurrence
[19] (Table 1). Obviously, cyclical Cushing’s syndrome
represents an additional cause of variable assay results.
Male sex is associated with slightly higher UFC levels
both in healthy subjects [20] and patients with Cushing’s
disease [3]. Increased urinary cortisol metabolites excre-
tion, e.g., tetrahydrocortisol, cortolones, has also been
reported in men [21] whereas decreased 11ß-hydroxys-
teroid dehydrogenase activity is responsible for prevalence
of urinary 11-oxo over 11-hydroxymetabolites in women
[22]. This difference is maintained with aging, although
subtle decreases in UFC can be observed with age [23].
Lastly, as urinary excretion is reliant on renal function,
variations in diuresis may affect UFC measurements but
this does not appear to occur within physiological changes
in urine volume [24]. As compliance in providing full 24-h
urine collections must be assured, urinary creatinine is
measured to ascertain adequacy of collection; correction
for urinary creatinine is usually not necessary for 24 h
collections although some laboratories express UFC as ng/
mg creatinine.
Morning serum cortisol
Measurement of morning serum cortisol plays a minor role
in the diagnostic work-up of Cushing’s syndrome, as up to
50 % of patients will present values comprised in the
normal range [25]. However, several studies have reported
a significant correlation between morning serum cortisol
levels and specific features in patients with Cushing’s
syndrome, e.g., left ventricular mass index [26], hypoka-
lemia, and muscle atrophy [3]. Thus, although morning
serum cortisol does not play a significant role in estab-
lishing hypercortisolism, it may well represent a parameter
for end organ damage.
Conversely, after surgery, morning serum cortisol rep-
resents a good predictor for remission and risk of relapse
(Table 1), thus accuracy and precision in the low-normal
range are necessary. Quality assessment programs report
overall good interlaboratory and interkit precision (i.e.,
\10 %) [27] and interference with other steroids is a lesser
problem compared to urinary cortisol. Spuriously elevated
cortisol measurements may be recorded in patients on
metyrapone due to increased 11ß-deoxycortisol [28] and to
increased cortisol-binding globulin (CBG) in patients on
mitotane [29].
As regards intraindividual variability, measurements
over 20 min in the same subject show good repeatability
and it has been estimated that 3 measurements are
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sufficient to achieve a reliable estimate [16]. However,
given the biological variability of morning cortisol around
20 % [30], measurements may differ by ±8 lg/dl
(220 nmol/l) over time [16]. Further, seasonal variability
impacts women to a greater degree than men with up to
7 lg/dl (200 nmol/l) difference from spring to winter [31].
This is relevant to postsurgical evaluation, as morning
serum cortisol is often used to guide weaning off steroid
replacement therapy over several months after surgery.
Lastly, morning serum cortisol is higher in healthy men
than women [32] and an increase by 20 % has been shown
to occur with aging, i.e., from 50- to 80-year old individ-
uals, in both sexes [33].
Midnight cortisol
In contrast to morning cortisol, late evening or midnight
cortisol is clearly altered in patients with Cushing’s syn-
drome; indeed, absent circadian cortisol rhythmicity is a
hallmark of endogenous hypercortisolism. The measure-
ment of cortisol late at night—in serum or saliva—is used
as a screening procedure, to follow patients with cyclical
hypercortisolism, to establish response to treatment as well
as to determine relapse of hypercortisolism after surgery
(Table 1).
The standing of midnight cortisol in the diagnostic
work-up of Cushing’s syndrome is very much influenced
by logistics and health care costs. One the one side, hos-
pitalization in order to sample patients at midnight is not
feasible in some countries, on the other side, not all labo-
ratories are equipped to handle salivary specimens, given
that its main use, i.e., screening for Cushing’s syndrome,
does not justify the expense in high throughput clinical
labs. Thus, both approaches are still current.
Age has been shown to affect circadian rhythmicity, as
cortisol circadian dipping is blunted with aging [34]. This
phenomenon is slowly progressive and begins in the fourth
decade of life [23, 35], thus in the age range of Cushing’s
syndrome. As low cut-offs are desired to ensure maximal
sensitivity of nocturnal cortisol, the number of false posi-
tives predictably is higher in 40-year-old and older subjects
[23, 35].
Salivary cortisol is subject to some unique concerns
[36]. Only unbound cortisol can diffuse into the saliva and,
indeed, serum:salivary cortisol ratio is roughly 20:1. One
factor which can specifically interfere with salivary cortisol
measurement is salivary gland 11ß-hydroxysteroid dehy-
drogenase type 2 activity which converts cortisol into
cortisone and is responsible for 4–6fold higher salivary
cortisone vs cortisol concentrations [37]. The abundance of
cortisone may prove a significant interference in
immunoassays [38], as antibodies raised against cortisol
can cross-react with cortisone. In serum, where cortisone is
roughly 1/8 with respect to cortisol, cross-reactivity is a
negligible problem. Advantages of salivary cortisol are
ease of sample collection, e.g., drooling, salivette chewing,
long-term storage, and even shipment through regular mail.
Drawbacks are the absence of reference preparation, dif-
fering reference ranges, and considerable interassay vari-
ability. External quality assessment program for salivary
cortisol have been set up by several Institutions, e.g.,
College of American Pathologists, but divergences
between assays have already been proven to represent a
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Fig. 1 Variability of urinary free cortisol measurements (UFC).
Results of measurements on three successive 24 h collections in
healthy individuals (left panel) and patients with Cushing’s syndrome
(right panel). Each set of three connected dots represents an
individual. Dashed line is set at 80 lg/24 h, i.e., the upper limit of
the normal range for post-extraction radioimmunoassay (Coat-a-
Count, Diagnostic Products Corp, Los Angeles, U.S.A)
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considerable problem [39]. This translates into the neces-
sity for each lab to develop its own reference range, which
is feasible in research setting but not in routine clinical
practice; in fact, most clinical laboratories simply adopt
technical sheet normal ranges. Lack of harmonization
between assays is particularly evident when results
obtained from immunoassays are compared with chro-
matography with the former yielding higher results [40]
and the latter susceptible to false positives [41]. Further,
conditions such as obesity [40] and diabetes [35] are
accompanied by higher midnight salivary cortisol levels
per se. Along the same line, salivary cortisol may prove
misleading in pseudoCushing [42] or other conditions
suspicious for endogenous hypercortisolism [41].
One specific advantage of measuring free cortisol in
saliva is that CBG concentrations do not affect salivary
steroid ultrafiltration; thus, levels are unaffected by oral
contraceptives [37]. Conversely, serum cortisol, i.e., free
plus protein-bound cortisol, is inevitably affected by
increased CBG levels [43]. While this does not represent a
problem for morning serum cortisol values, it certainly
affects low, late evening cortisol levels [44]. No significant
sex-related difference was observed in serum and salivary
midnight cortisol in either patients with Cushing’s syn-
drome or healthy subjects [45].
Midnight serum cortisol concentrations over successive
nights were proven to be by and large comparable in
healthy or hypercortisolemic individuals [46]. Conversely,
reproducibility of midnight salivary cortisol over time is
not consistent over time; indeed intraindividual variability
in measurements was as high as 22 % in healthy individ-
uals, over 30 % in Cushing’s syndrome suspects, and twice
as much in patients with Cushing’s syndrome [47, 48]
(Fig. 2). Inevitably, this leads to some discordant classifi-
cation of normal and abnormal values in repeat salivary
measurements among subjects suspected of Cushing’s
Table 1 Issues associated with hormonal assays used in the management of Cushing’s syndrome
Parameter Sampling Use Specific issues Possible solutions
Urinary free
cortisol
Circadian secretion
After 8 mg dexamethasone
Diagnosis
Response to treatment
Follow-up
Interference due to cortisol
metabolites
Urine extraction,
chromatographic
assays
Completeness of 24 h urine
collection
Urinary creatinine
Interferences due to medications Case history
Day-to-day variability Multiple sampling
Gender Sex-specific normal
ranges
Salivary
cortisol
Late evening Diagnosis
Response to treatment
Follow-up
Assay-related variability
Aging
Day-to-day variability
Assay standardization
Age-adjusted ranges
Multiple sampling
Serum
cortisol
Morning After surgery Increased CBG, e.g.,
contraceptives
Case history
Biological variability Multiple sampling
Gender Sex-specific ranges
Late evening Diagnosis Increased CBG
Aging
After low and high dose
dexamethasone
Diagnosis
Response to treatment
Follow-up
Dexamethasone bioavailability,
clearance
Plasma dexamethasone
assay
GR polymorphisms GR gene analysis
Increased CBG, e.g.,
contraceptives
Case history
Aging Age-adjusted ranges
Assay variability Assay-specific cut-offs
After CRH stimulation Differential diagnosis Increased CBG Case history
Plasma
ACTH
Morning Differential diagnosis Pulsatility, short half-life
Assay-related variability
Multiple sampling
Assay standardization
After CRH stimulation
During IPSS
Differential diagnosis No specific issue
CRH corticotropin-releasing hormone, IPSS inferior petrosal sinus sampling, CBG cortisol-binding globulin, GR glucocorticoid receptor
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syndrome [41, 48]. This issue becomes particularly rele-
vant in mild Cushing’s syndrome in whom normal salivary
values may be recorded repeatedly over time [49] and only
a high degree of clinical suspicion leads to the correct
diagnosis.
Dexamethasone suppression tests
Dexamethasone suppression tests play a role in both the
diagnosis and the differential diagnosis of Cushing’s syn-
drome. Low-dose tests (1 mg overnight, i.e., overnight
suppression test, OST, or 2 mg over 2 days) are used to
identify patients with Cushing’s syndrome whereas high-
dose dexamethasone tests (8 or 16 mg) are employed to
distinguish between pituitary and ectopic ACTH secretion
or to evoke a paradoxical cortisol response in adrenal
nodular dysplasia. Low-dose tests are also used to define
remission after surgery or medical therapy (Table 1).
For low-dose tests, cortisol is measured in serum, pos-
sibly also in saliva, whereas measurements in both serum
and 24 h urine are used for the high-dose test. Interpreta-
tion of low-dose test requires judging whether the patient’s
cortisol concentration is above or below a given diagnostic
cut-off; on the other hand, for the high-dose dexametha-
sone test, pre- and post-dexamethasone cortisol concen-
trations are compared and the degree of change weighed
against specific thresholds. Thus, differences between
assays primarily affect the low-dose suppression test, far
less than the high-dose suppression test.
The issue of assay-specific cut-offs had been raised
already 30 years ago [50] at the time of radioimmunoas-
says (RIA), but still represents a problem with current
chemiluminescent assays [51]. This resulted in higher
cortisol levels if patient samples are measured with one or
another assay and, thus, the diagnosis ‘‘non-suppression’’
or ‘‘suppression’’ was assay kit-dependent [51]. As regards
repeatability of dexamethasone suppression over time,
cortisol concentrations with repeat 0.25 mg dexamethasone
testing in normal subjects ranged from 50 to 200 % of the
first measurement [52]. Discrepancies between test results
may prove relevant when OST is performed repeatedly in
the same subject, for example in patients with mild
hypercortisolism [53], to establish remission after surgery
[54] or medical therapy [55] and relapse after successful
surgery [56]. Diagnostic accuracy of salivary cortisol after
dexamethasone suppression has also been evaluated but
specificity appears less than that of serum cortisol [57].
The high-dose dexamethasone test has withstood the test
of time less brilliantly than the low-dose test and its sub-
optimal sensitivity and specificity led some authors advo-
cate its abandonment [1]. However, given the difficulties
with CRH supplies and IPSS availability, this test remains
the only available means to attempt the differential diag-
nosis of ACTH-dependent Cushing’s syndrome in several
endocrine centers. Assay-dependent differences in dex-
amethasone-suppressed serum cortisol measurements have
been reported for the 8 mg test in normal and pseu-
doCushing subjects [51]; as the diagnostic criterion for the
high-dose test is the percentage decrease from pre-dex-
amethasone cortisol concentrations, this difference may not
be relevant to the diagnostic work-up. As regards urinary
cortisol, the same assay-related difficulties reported for
baseline UFC apply although intraindividual variability of
suppressed cortisol secretion may be less than that of
spontaneous concentrations. Reproducibility of cortisol
inhibition after high dexamethasone suppression is as yet
unknown.
In addition to factors associated with cortisol assays, the
response to dexamethasone suppression is affected by
bioavailability and clearance of dexamethasone. Dexam-
ethasone plasma concentrations vary considerably in
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Fig. 2 Variability of midnight salivary cortisol measurements.
Results of measurements on 2–4 successive collections in healthy
individuals (left panel) and patients with Cushing’s syndrome (right
panel). Each set of three connected dots represents an individual.
Dashed line is set at 0.35 lg/dl, i.e., the upper limit of the normal
range (Elecsys, Roche Diagnostics, Mannheim, Germany)
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subjects administered the same oral dose [58] and are
clearly higher in subjects who suppress than in non-sup-
pressors [59]. This has been shown to occur after both oral
and intravenous administration and appears associated with
differences in dexamethasone clearance and plasma half-
life [59]. The effect of drugs such as phenytoin, rifampicin,
and carbamazepine, which accelerate hepatic metabolism,
is well known and may lead to false positive results.
Measurement of plasma dexamethasone concurrently with
serum cortisol has been advocated [60] but proved
impractical and too expensive for a screening test in clin-
ical practice.
Aging appears associated with resistance to negative
feedback [61] and older subjects are more likely to present
unsuppressed cortisol levels; this applies both to normal
individuals [50] and Cushing’s syndrome suspects [23],
thus increasing the risk for false positives. Weight is
inversely correlated with sensitivity to low dose, i.e.,
0.05–0.125 mg, dexamethasone inhibition [62] but sensi-
tivity of the 1 mg dexamethasone suppression test appears
unaffected by weight [63].
Gender does not appear to play a significant role in
sensitivity to dexamethasone suppression [45] although,
obviously, women in child-bearing age must not be on oral
contraceptives as the increase in CBG may lead to
increased false positives [64]. This may particularly be
relevant to screening of obese or diabetic patients, as
contraceptives are often not perceived to be true medica-
tions and may not be reported by patients prior to testing.
Another factor which might affect the sensitivity to
dexamethasone suppression are glucocorticoid receptor
polymorphisms. Individuals carrying the ER22/23EK
variant are more likely to present higher cortisol levels
after low-dose dexamethasone suppression whereas carri-
ers of the N363S and Bcl1 polymorphisms present lower
cortisol levels [65]. A recent study has shown that the Bcl1
polymorphism does not impact cortisol levels after OST in
patients with Cushing’s disease [66] but whether this holds
true also for low cortisol levels, i.e., normal individuals or
Cushing’s syndrome suspects, remains to be tested.
Plasma ACTH
Plasma ACTH is pivotal to the differential diagnosis of
Cushing’s syndrome, both as regards ACTH-dependency
versus ACTH-independency and pituitary versus ectopic
ACTH-secreting tumors. ACTH is measured in unchal-
lenged samples or after stimulation with corticotrophin-
releasing hormone (CRH) both as a standalone test or
during inferior petrosal sinus sampling (IPSS).
Measurement of ACTH has to take into account several
factors, in particular its highly pulsatile secretory pattern,
short plasma half-life—approx. 15 min [67]—and assay-
related concerns. Foremost issue is the marked pulsatility
of ACTH secretion, both in terms of pulse frequency and
pulse amplitude [68], thus reliable estimates of plasma
ACTH concentrations can be obtained only through mul-
tiple sampling (Fig. 3). Further, technical issues are known
to affect plasma ACTH measurements, both in the prean-
alytical and analytical phase [69]. Appropriate use of
anticoagulants, e.g., EDTA, siliconized glass tubes, rapid
chilling, have been shown to improve ACTH analysis,
although ACTH remains one of the less stable hormonal
analytes [70]. As regards the analytical phase, the absence
of an international ACTH reference standard means that
each assay uses its own reference preparation and this
leaves the issue of assay accuracy, i.e., true ACTH (1–39)
concentrations, unresolved [71]. Indeed, considerable
variability among ACTH measurements performed in
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Fig. 3 Variability of plasma ACTH measurements. Results of repeat
sampling from an indwelling venous catheter over 60 min in healthy
individuals (left panel) and patients with Cushing’s syndrome (right
panel). Each set of three connected dots represents an individual.
Dashed line is set at 80 pg/ml, i.e., upper limit of the normal range for
immunometric chemiluminescent assay (Elecsys, Roche Diagnostics,
Mannheim, Germany)
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different laboratories with different assay kits was recently
reported [72], in line with results of external quality
assessment programs showing 7–22 % coefficient of vari-
ation among ACTH assays [73]. To the clinician, the
widely differing normal ranges reported by assay manu-
facturers, ranging from \46 pg/ml (\10 pmol/l) to
10–90 pg/ml (2.2–19.8 pmol/l), are an intuitive index of
lack of assay standardization.
Demographic factors, i.e., age and sex, play a minor role
although women present slightly lower ACTH concentra-
tions than men, both in healthy individuals [74] and in
patients with Cushing’s disease [3]. Further, oral contra-
ceptives are associated with somewhat lower plasma
ACTH levels [75].
In Cushing’s disease, the ACTH-secreting tumor pro-
duces ACTH autonomously but, at variance with other
pituitary tumors, e.g., GH- or prolactin-secreting, increased
pituitary hormone levels are not mandatory to establish the
diagnosis. Indeed, ACTH concentrations may well be
comprised within the normal range in Cushing’s disease
[25, 76] and, to a lesser extent, this is also true for ectopic
ACTH secretion [25, 77]. In addition, plasma ACTH after
surgery, again in contrast to other pituitary tumors,
decreases but is not a clear indicator of remission [78] and,
likewise, changes in plasma ACTH during medical therapy
are less obvious responses to treatment [17, 18]. This
suggests that measurement of ACTH per se is a poor
indicator of corticotroph tumor activity, and, indeed,
ACTH levels are poorly correlated with other markers of
hypercortisolism, e.g., UFC, cortisol after low-dose dex-
amethasone (Fig. 4). It is worth recalling that in addition to
marked amplification and greater disorderliness, ACTH
secretion appears less synchronized with cortisol release in
patients with Cushing’s disease [79].
In the differential diagnosis between ACTH-dependent
and ACTH-independent Cushing’s syndrome, greater reli-
ance is placed in accuracy of low rather than high ACTH
measurements. Recent studies have shown, however, that
reliability of low ACTH measurements is far from absolute
and a consistent number of patients with adrenal adenoma,
carcinoma, nodular dysplasia, or nodular hyperplasia pre-
sent unsuppressed or even normal plasma ACTH levels
[25, 80]. In fact, ACTH measurements proved misleading
in up to 40 % of patients with adrenal Cushing’s syndrome
[72, 76].
As regards assay methodology, comparison between
competitive, single-antibody RIA and sandwich, two-site
immunometric revealed that human plasma contains dif-
ferent ACTH species which can variably affect assay
results. In fact, immunometric assays often yielded higher
ACTH values than RIA in patients with Cushing’s disease
[81, 82] whereas the opposite was observed in patients with
ectopic secretion [81], in whom POMC and ACTH
processing may follow alternative pathways. In most lab-
oratories, RIA has been superseded by non-competitive
radiometric or chemiluminescent assays but, even among
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Fig. 4 Lack of correlation between plasma ACTH and markers of
hypercortisolism in patients with Cushing’s disease. Regression plot
between ACTH and urinary free cortisol (upper panel), between
ACTH and serum cortisol at midnight (middle panel) and between
ACTH and cortisol after 1 mg dexamethasone
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the latter, some will yield up to 20 % higher measurements
than others [83]. In fact, although correlation between
measurements was statistically sound, deviances in the
lower assay range [72, 82] may prove clinically significant
for the differential diagnosis of Cushing’s syndrome.
As regards CRH testing and IPSS, both these procedures
require comparison of ACTH measurements, i.e., baseline
versus stimulated or central versus peripheral, thus a pos-
sible assay-related bias is unlikely to affect diagnostic
accuracy [82]. Previous studies on CRH testing showed
that repeat 100 lg human CRH administration to normal
subjects yielded superimposable ACTH peak responses
[84]; it has been our experience that ACTH responses in
patients with Cushing’s disease, both in the active phase
and after long-term remission are by and large similar in a
given individual (Pecori Giraldi, unpublished data). In
those rare cases in whom repeat IPSS was performed due to
contrasting imaging and hormonal findings, test results
proved comparable [85].
Conclusions
Measurements of cortisol and ACTH in serum, urine, or
saliva are subject to considerable variability, inherent to
hormonal secretion and assay methodology. On the one
side, irregularity in hormone secretion is accentuated in
Cushing’s syndrome and complicates disease assessment.
On the other side, assay platforms for urinary as well as
salivary cortisol lack harmonization and measurement of
ACTH plasma is susceptible to a variety of confounders.
Measured concentrations of either hormone appear as an
approximate marker of tumoral hypersecretion and dis-
ease activity and major efforts should be expended by
the endocrinological community in order to close this
gap and ameliorate soundness of cortisol and ACTH
assays.
Altogether, interpretation of ACTH and cortisol mea-
surements requires clinical expertise coupled with the
knowledge that no single measurement is 100 % accurate
for the diagnosis and, by inference, management of
Cushing’s syndrome.
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